GCC Biosimilar Market Overview:
The GCC biosimilar market was worth US$ XX Billion in 2019, expanding at a CAGR of X% during 2012-2019. The market is projected to register a CAGR of X% during 2020-2025, reaching US$ XX Billion by 2025.The GCC biosimilars market is currently growing at a healthy growth rate. Biosimilars, also known as subsequent entry biologic or follow-on biologic, are generic non-patented chemical and therapeutic equivalents of brand name biopharmaceutical drugs. These drugs are different from generic drugs as they exhibit a high molecular complexity. They possess similar medical properties in terms of potency, safety, and efficacy to original biologic products. Due to the cost-effectiveness and the rising incidence of chronic diseases such as diabetes, cancer, growth hormone deficiency, and anaemia, the demand for biosimilar drugs is increasing in the GCC countries. The introduction of biosimilars has led to improved access to the premium-priced biopharmaceuticals at lesser costs. In addition, the increasing investments in research and development activities coupled with favourable policies to accelerate approvals of biosimilar drugs is also boosting the market growth in the GCC region.
GCC Biosimilar Market Segment Insights:
The report has assessed the GCC biosimilar market on the basis of molecule covering, infliximab, insulin glargine, epoetin alfa, etanercept, filgrastim, somatropin, rituximab and follitropin alfa. The report has further examined the market based on type of manufacturing including, In-house manufacturing and contract manufacturing. On the basis of indication covering, auto-immune diseases, blood disorder, diabetes, oncology, growth deficiency and female infertility. On a regional basis, the report examines the biosimilar market in Saudi Arabia, United Arab Emirates, Qatar, Kuwait, Oman and Bahrain. An evaluation of the competitive landscape has also been provided with the details of the key players operating in the GCC biosimilar market.
Highlights of the GCC Biosimilar Market Report:
Key Market Segments:
The GCC biosimilar market has been analysed as followed:
Segmentation by Molecule:
Segmentation by Type of Manufacturing:
Segmentation by Indication:
Segmentation by Country:
Report Customisation:
The GCC biosimilar market report can be customised as per your requirements. You can get in touch with our analyst, who will make sure that the report suits your research needs
1 Introduction
1.1 Research Objectives
1.2 Stakeholders
1.3 Scope of the Report
1.4 Assumptions and Limitations
2 Research Methodology
2.1 Data Collection
2.1.1 Primary Sources
2.1.2 Secondary Sources
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Data Validation
3 Executive Summary
4 Introduction to Global Biosimilar Market
4.1 Overview
4.2 WHO and FDA Terminology on Biosimilars
4.3 Biosimilars and Generics
4.3 Biosimilars and Branded Biological Products
5 Biosimilar Research, Development and Manufacturing
5.1 Research and Development: Biosimilars vs. Innovator Drugs
5.2 Manufacturing: Biosimilars vs. Innovator Drugs
6 Global Biosimilar Market
6.1 Historical Market Trends
6.2 Market Segmentation by Region
6.3 Market Outlook
7 GCC Biosimilar Market
7.1 Industry Overview
7.2 Key Industry Developments
7.3 Market Trends
7.3.1 Key Market Indicators
7.3.2 Historical Market Trends
7.3.3 Market Outlook
8 GCC Biosimilar Market Segmentation by Country
8.1 Saudi Arabia
8.1.1 Historical Market Trends
8.1.2 Market Outlook
8.2 United Arab Emirates
8.2.1 Historical Market Trends
8.2.2 Market Outlook
8.3 Qatar
8.3.1 Historical Market Trends
8.3.2 Market Outlook
8.4 Kuwait
8.4.1 Historical Market Trends
8.4.2 Market Outlook
8.5 Oman
8.5.1 Historical Market Trends
8.5.2 Market Outlook
8.6 Bahrain
8.6.1 Historical Market Trends
8.6.2 Market Outlook
9 GCC Biosimilar Market Segmentation by Module
9.1 Infliximab
9.1.1 Historical Market Trends
9.1.2 Market Outlook
9.2 Insulin Glargine
9.2.1 Historical Market Trends
9.2.2 Market Outlook
9.3 Epoetin Alfa
9.3.1 Historical Market Trends
9.3.2 Market Outlook
9.4 Etanercept
9.4.1 Historical Market Trends
9.4.2 Market Outlook
9.5 Filgrastim
9.5.1 Historical Market Trends
9.5.2 Market Outlook
9.6 Somatropin
9.6.1 Historical Market Trends
9.6.2 Market Outlook
9.7 Rituximab
9.7.1 Historical Market Trends
9.7.2 Market Outlook
9.8 Follitropin Alfa
9.8.1 Historical Market Trends
9.8.2 Market Outlook
10 GCC Biosimilar Market Segmentation by Type of Manufacturing
10.1 In-House Manufacturing
10.1.1 Historical Market Trends
10.1.2 Market Outlook
10.2 Contract Manufacturing
10.2.1 Historical Market Trends
10.2.2 Market Outlook
11 GCC Biosimilar Market Segmentation by Indication
11.1 Auto-Immune Diseases
11.1.1 Historical Market Trends
11.1.2 Market Outlook
11.2 Blood Disorder
11.2.1 Historical Market Trends
11.2.2 Market Outlook
11.3 Diabetes
11.3.1 Historical Market Trends
11.3.2 Market Outlook
11.4 Oncology
11.4.1 Historical Market Trends
11.4.2 Market Outlook
11.5 Growth Deficiency
11.5.1 Historical Market Trends
11.5.2 Market Outlook
11.6 Female Infertility
11.6.1 Historical Market Trends
11.6.2 Market Outlook
12 GCC Biosimilar Industry: Market Dynamics
12.1 Overview
12.2 Strengths
12.3 Weaknesses
12.4 Opportunities
12.5 Threats
13 GCC Biosimilar Industry: Value Chain Analysis
13.1 Overview
13.2 Research and Development
13.3 Raw Material Suppliers
13.4 Inbound Logistics
13.5 Production
13.6 Marketing
13.7 Outbound Logistics
13.8 Consumers
14 GCC Biosimilar Industry: Porter’s Five Forces Analysis
14.1 Overview
14.2 Threat of New Entrants
14.3 Threat of Substitutes
14.4 Bargaining Power of Buyers
14.5 Bargaining Power of Suppliers
14.6 Intensity of Rivalry
15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Key Success Factors
16 Key Player Profiles
List of Figures
Figure 1: Global: Biosimilar Market: Sales Value (in Million US$), 2012-2019
Figure 2: Global: Biosimilar Market: Segmentation by Region (in %), 2019
Figure 3: Global: Biosimilar Market Outlook: Sales Value (in Million US$), 2020-2025
Figure 4: GCC: Biosimilar Market: Sales Value (in Million US$), 2012-2019
Figure 5: GCC: Biosimilar Market Outlook: Sales Value (in Million US$), 2020-2025
Figure 6: GCC: Biosimilar Market: Segmentation by Country (in %), 2019
Figure 7: GCC: Biosimilar Market: Segmentation by Molecule (in %), 2019
Figure 8: GCC: Biosimilar Market: Segmentation by Type of Manufacturing (in %), 2019
Figure 9: GCC: Biosimilar Market: Segmentation by Indication (in %), 2019
Figure 10: Saudi Arabia: Biosimilar Market: Sales Value (in Million US$), 2012 & 2019
Figure 11: Saudi Arabia: Biosimilar Market Outlook: Sales Value (in Million US$), 2020-2025
Figure 12: United Arab Emirates: Biosimilar Market: Sales Value (in Million US$), 2012 & 2019
Figure 13: United Arab Emirates: Biosimilar Market Outlook: Sales Value (in Million US$), 2020-2025
Figure 14: Qatar: Biosimilar Market: Sales Value (in Million US$), 2012 & 2019
Figure 15: Qatar: Biosimilar Market Outlook: Sales Value (in Million US$), 2020-2025
Figure 16: Kuwait: Biosimilar Market: Sales Value (in Million US$), 2012 & 2019
Figure 17: Kuwait: Biosimilar Market Outlook: Sales Value (in Million US$), 2020-2025
Figure 18: Oman: Biosimilar Market: Sales Value (in Million US$), 2012 & 2019
Figure 19: Oman: Biosimilar Market Outlook: Sales Value (in Million US$), 2020-2025
Figure 20: Bahrain: Biosimilar Market: Sales Value (in Million US$), 2012 & 2019
Figure 21: Bahrain: Biosimilar Market Outlook: Sales Value (in Million US$), 2020-2025
Figure 22: GCC: Biosimilar (Infliximab) Market: Sales Value (in Million US$), 2012 & 2019
Figure 23: GCC: Biosimilar (Infliximab) Market Outlook: Sales Value (in Million US$), 2020-2025
Figure 24: GCC: Biosimilar (Insulin Glargine) Market: Sales Value (in Million US$), 2012 & 2019
Figure 25: GCC: Biosimilar (Insulin Glargine) Market Outlook: Sales Value (in Million US$), 2020-2025
Figure 26: GCC: Biosimilar (Epoetin Alfa) Market: Sales Value (in Million US$), 2012 & 2019
Figure 27: GCC: Biosimilar (Epoetin Alfa) Market Outlook: Sales Value (in Million US$), 2020-2025
Figure 28: GCC: Biosimilar (Etanercept) Market: Sales Value (in Million US$), 2012 & 2019
Figure 29: GCC: Biosimilar (Etanercept) Market Outlook: Sales Value (in Million US$), 2020-2025
Figure 30: GCC: Biosimilar (Filgrastim) Market: Sales Value (in Million US$), 2012 & 2019
Figure 31: GCC: Biosimilar (Filgrastim) Market Outlook: Sales Value (in Million US$), 2020-2025
Figure 32: GCC: Biosimilar (Somatropin) Market: Sales Value (in Million US$), 2012 & 2019
Figure 33: GCC: Biosimilar (Somatropin) Market Outlook: Sales Value (in Million US$), 2020-2025
Figure 34: GCC: Biosimilar (Rituximab) Market: Sales Value (in Million US$), 2012 & 2019
Figure 35: GCC: Biosimilar (Rituximab) Market Outlook: Sales Value (in Million US$), 2020-2025
Figure 36: GCC: Biosimilar (Follitropin Alfa) Market: Sales Value (in Million US$), 2012 & 2019
Figure 37: GCC: Biosimilar (Follitropin Alfa) Market Outlook: Sales Value (in Million US$), 2020-2025
Figure 38: GCC: Biosimilar (In-house Manufacturing) Market: Sales Value (in Million US$), 2012 & 2019
Figure 39: GCC: Biosimilar (In-house Manufacturing) Market Outlook: Sales Value (in Million US$), 2020-2025
Figure 40: GCC: Biosimilar (Contract Manufacturing) Market: Sales Value (in Million US$), 2012 & 2019
Figure 41: GCC: Biosimilar (Contract Manufacturing) Market Outlook: Sales Value (in Million US$), 2020-2025
Figure 42: GCC: Biosimilar (Auto-Immune Diseases) Market: Sales Value (in Million US$), 2012 & 2019
Figure 43: GCC: Biosimilar (Auto-Immune Diseases) Market Outlook: Sales Value (in Million US$), 2020-2025
Figure 44: GCC: Biosimilar (Blood Disorder) Market: Sales Value (in Million US$), 2012 & 2019
Figure 45: GCC: Biosimilar (Blood Disorder) Market Outlook: Sales Value (in Million US$), 2020-2025
Figure 46: GCC: Biosimilar (Diabetes) Market: Sales Value (in Million US$), 2012 & 2019
Figure 47: GCC: Biosimilar (Diabetes) Market Outlook: Sales Value (in Million US$), 2020-2025
Figure 48: GCC: Biosimilar (Oncology) Market: Sales Value (in Million US$), 2012 & 2019
Figure 49: GCC: Biosimilar (Oncology) Market Outlook: Sales Value (in Million US$), 2020-2025
Figure 50: GCC: Biosimilar (Growth Deficiency) Market: Sales Value (in Million US$), 2012 & 2019
Figure 51: GCC: Biosimilar (Growth Deficiency) Market Outlook: Sales Value (in Million US$), 2020-2025
Figure 52: GCC: Biosimilar (Female Infertility) Market: Sales Value (in Million US$), 2012 & 2019
Figure 53: GCC: Biosimilar (Female Infertility) Market Outlook: Sales Value (in Million US$), 2020-2025
Figure 54: GCC: Biosimilar Industry: Market Dynamics
Figure 55: GCC: Biosimilar Industry: Value Chain Analysis
Figure 56: GCC: Biosimilar Market: Porter’s Five Forces Analysis
List of Tables
Table 1: GCC: Biosimilar Market: Key Industry Highlights, 2019 and 2025
Table 2: GCC: Biosimilar Market Outlook: Segmentation by Country (in Million US$), 2020-2025
Table 3: GCC: Biosimilar Market Outlook: Segmentation by Molecule (in Million US$), 2020-2025
Table 4: GCC: Biosimilar Market Outlook: Segmentation by Type of Manufacturing (in Million US$), 2020-2025
Table 5: GCC: Biosimilar Market Outlook: Segmentation by Indication (in Million US$), 2020-2025
Table 6: GCC: Biosimilar Market Structure
Table 7: GCC: Biosimilar Market: Key Players
Special Prices
Shrimp belongs to the largest category of crustaceans called Malacostraca and is characterized by an elongated body with long antennae and legs.
Frozen foods include a wide variety of ready-to-cook and convenience food items ranging from meat and fish to fruits and vegetables.
Ginger is a commonly used condiment with a pungent, slightly sweet and peppery flavor and spicy aroma.
Chocolate refers to an edible product usually prepared from roasted and ground cocoa seeds obtained from the pods of the Theobroma cacao trees.
The hot sauce manufacturing plant project report offers an in-depth roadmap or setting up a hot sauce manufacturing plant covering the essential techno-commercial aspects.